Vanda Pharmaceuticals (VNDA) EBIAT (2016 - 2025)
Vanda Pharmaceuticals' EBIAT history spans 16 years, with the latest figure at -$141.2 million for Q4 2025.
- For Q4 2025, EBIAT fell 2774.86% year-over-year to -$141.2 million; the TTM value through Dec 2025 reached -$220.5 million, down 1066.67%, while the annual FY2025 figure was -$220.5 million, 1066.53% down from the prior year.
- EBIAT for Q4 2025 was -$141.2 million at Vanda Pharmaceuticals, down from -$22.6 million in the prior quarter.
- Across five years, EBIAT topped out at $9.7 million in Q2 2021 and bottomed at -$141.2 million in Q4 2025.
- The 5-year median for EBIAT is -$1.1 million (2023), against an average of -$9.9 million.
- The largest annual shift saw EBIAT surged 1679.84% in 2021 before it tumbled 3986.13% in 2024.
- A 5-year view of EBIAT shows it stood at $7.1 million in 2021, then dropped by 3.07% to $6.9 million in 2022, then tumbled by 134.98% to -$2.4 million in 2023, then crashed by 104.67% to -$4.9 million in 2024, then plummeted by 2774.86% to -$141.2 million in 2025.
- Per Business Quant, the three most recent readings for VNDA's EBIAT are -$141.2 million (Q4 2025), -$22.6 million (Q3 2025), and -$27.2 million (Q2 2025).